business

Volition Expands Fujifilm Deal to Cover Feline Cancer Blood Test

Summarized from All Financial Services & Investing

VolitionRx extends its Fujifilm contract to include a cat-focused liquid biopsy test, targeting Japan's nearly nine million cats.

Volition Expands Fujifilm Deal to Cover Feline Cancer Blood Test

VolitionRx Limited has broadened its existing contract with Fujifilm to encompass the Nu.Q Vet Feline Test, a blood-based cancer screening tool designed specifically for cats, the Nevada-based company announced Monday from Henderson.

The expansion opens the door to Japan's feline population of nearly nine million animals, representing a substantial commercial opportunity for the diagnostic technology. Volition says the test is designed to be simple and affordable, two attributes the company believes are critical to widespread veterinary adoption.

Read more Xtant Medical Posts Q3 2026 Results, Launches Strategic Review →

If cleared for market, the Nu.Q Vet Feline Test would become what Volition describes as the world's first liquid biopsy blood test built exclusively for cancer detection in cats. Liquid biopsy technology works by identifying biological markers in a blood sample rather than requiring invasive tissue procedures, a significant advantage in veterinary settings where minimizing patient stress is a clinical priority.

The move follows Volition's earlier contract with Fujifilm covering canine applications of the Nu.Q Vet platform, suggesting a deliberate strategy to broaden the technology's reach across companion animal species. Analysts tracking the veterinary diagnostics sector have noted growing demand for non-invasive cancer screening tools as pet ownership and spending on animal healthcare rise across developed markets, particularly in Asia.

Volition has not disclosed financial terms of the expanded agreement. Continue reading at All Financial Services & Investing.

Frequently Asked Questions

Q.What is the Nu.Q Vet Feline Test?

The Nu.Q Vet Feline Test is a blood-based liquid biopsy test developed by VolitionRx to detect cancer in cats. The company says it is designed to be simple and affordable, and claims it would be the world's first such test specifically for felines.

Q.Why is Fujifilm involved in this cat cancer test?

VolitionRx has an existing contract with Fujifilm that originally covered canine applications of its Nu.Q Vet technology. The new agreement expands that partnership to include the feline version of the test.

Q.How large is the potential market for this test in Japan?

Japan has nearly nine million cats, according to Volition, representing the addressable market the company aims to reach through its expanded deal with Fujifilm.

More in business →